ABSTRACT
A Bayesian-derived area-under-the-curve from 0 to 24 h to minimum inhibitory concentration (AUC24/MIC) of 400 to 600 has been recommended as the pharmacokinetic/pharmacodynamic (PK/PD) target of vancomycin (VAN) treatment in adults. However, limited data exists in neonates to support this target. Therefore, this study aimed: (i) to develop a population PK model to characterize significant covariates and to estimate AUC; (ii) to determine the neonatal PK/PD target of VAN and potential influence factors on this target; (iii) to design neonatal VAN recommendation based on the evaluated target. A single center retrospective observational cohort study was conducted. A population PK model was established by using Monolix 2019R2. Acute kidney injury (AKI) for all 182 patients were screened to determine the upper limit of VAN exposure. Clinical efficacy of 42 patients with blood culture proved staphylococcal sepsis was analyzed, and the threshold in predicting efficacy was developed as the lower limit of exposure. AUC24 ⩾ 623 (mg·h)/liter and concomitant use of VAS were independent risks for AKI. When adjusted by current body weight (cWT) < 1.3 kg, AUC24/MIC < 242 was highly correlated with treatment failure. AUC24/MIC of 250 to 600 with MIC assumed to 1 mg/liter was set as the optimal PK/PD target in neonates then dosing recommendation was designed. In conclusion, AUC24/MIC is a good predictor for VAN toxicity and efficacy in neonates. The designed regimens are valuable for neonatal individualized dosing in ICU setting. (This study has been registered at chictr.org.cn under identifier ChiCTR1900027919.)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study has been registered at chictr.org.cn under identifier ChiCTR1900027919
Funding Statement
This project was partly supported by the National Science Foundation for Young Scientists of China (No.) and Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (No. 2019YX004).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data of this study will be open to public through public access of medresman.org.cn within 6 months after publication.
http://www.medresman.org.cn/pub/cn/proj/projectshshow.aspx?proj=1448